Abstract
BACKGROUND: To describe participation in clinical trials among HIV-positive women enrolled since 1993 in the Canadian Women's HIV Study, a prospective open cohort study. METHODS: All HIV-positive women being followed at hospital-based or community-based clinics at 28 sites in 11 Canadian cities were eligible to participate in the Canadian Women's HIV Study. Baseline and follow-up information was collected for 413 women every 6 months by study nurses using standardized questionnaires. Data included sociodemographic variables, HIV exposure group, CD4 count, disease classification, use of antiretroviral therapies and participation in clinical trials. RESULTS: At study intake 15.0% (62/413) of the women had participated in a clinical trial; an additional 8.5% (35/413) participated during a median follow-up of 18 months. Multivariate analysis revealed that the following factors were independently associated with participation in a clinical trial: white race (adjusted odds ratio [OR] 3.38, p = 0.001), current use of antiretroviral therapy (adjusted OR 2.01, p = 0.008), completion of secondary school (adjusted OR 1.97, p = 0.024) and residence in the Prairies or Atlantic provinces (adjusted OR 1.98, p = 0.043). INTERPRETATION: Although the overall clinical trial participation rate of 23.5% was relatively high among HIV-positive women, injection drug users were underrepresented in this study population, and non-white women, women who did not complete high school and women not receiving antiretroviral therapy were less likely than white women, women of higher education and women receiving antiretroviral therapy to participate in clinical trials in Canada. Because of the importance of trial participants being representative of the population for which therapeutic agents are intended, HIV clinical trials must recruit women with lower literacy levels, non-white women, women not receiving antiretroviral therapy and women who are injection drug users to ensure generalizability of research findings. Further study is needed to assess factors that act as barriers and motivators to women's participation in HIV clinical trials.
Full Text
The Full Text of this article is available as a PDF (142.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Angell M. Caring for women's health--what is the problem? N Engl J Med. 1993 Jul 22;329(4):271–272. doi: 10.1056/NEJM199307223290409. [DOI] [PubMed] [Google Scholar]
- Bennett J. C. Inclusion of women in clinical trials--policies for population subgroups. N Engl J Med. 1993 Jul 22;329(4):288–292. doi: 10.1056/NEJM199307223290428. [DOI] [PubMed] [Google Scholar]
- Cohen J. Women: absent term in the AIDS research equation. Science. 1995 Aug 11;269(5225):777–780. doi: 10.1126/science.7638589. [DOI] [PubMed] [Google Scholar]
- Cotton D. J., Finkelstein D. M., He W., Feinberg J. Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection. The AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1993 Dec;6(12):1322–1328. [PubMed] [Google Scholar]
- Diaz T., Chu S. Y., Sorvillo F., Mokotoff E., Davidson A. J., Samuel M. C., Herr M., Doyle B., Frederick M., Fann S. A. Differences in participation in experimental drug trials among persons with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):562–568. [PubMed] [Google Scholar]
- Hankins C. A. Ten years of AIDS: AIDS has changed medicine and the way it is practised. CMAJ. 1992 Feb 1;146(3):381–382. [PMC free article] [PubMed] [Google Scholar]
- Healy B. The Yentl syndrome. N Engl J Med. 1991 Jul 25;325(4):274–276. doi: 10.1056/NEJM199107253250408. [DOI] [PubMed] [Google Scholar]
- Kunkel S. R., Atchley R. C. Why gender matters: being female is not the same as not being male. Am J Prev Med. 1996 Sep-Oct;12(5):294–296. [PubMed] [Google Scholar]
- Martinez R. M. Why race and gender remain important in health services research. Am J Prev Med. 1996 Sep-Oct;12(5):316–318. [PubMed] [Google Scholar]
- McGovern T., Davis M., Caschetta M. B. Inclusion of women in AIDS clinical research: a political and legal analysis. J Am Med Womens Assoc. 1994 Jul-Aug;49(4):102-4, 109. [PubMed] [Google Scholar]
- Merkatz R. B., Temple R., Subel S., Feiden K., Kessler D. A. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med. 1993 Jul 22;329(4):292–296. doi: 10.1056/NEJM199307223290429. [DOI] [PubMed] [Google Scholar]
- Morse E. V., Simon P. M., Besch C. L., Walker J. Issues of recruitment, retention, and compliance in community-based clinical trials with traditionally underserved populations. Appl Nurs Res. 1995 Feb;8(1):8–14. doi: 10.1016/s0897-1897(95)80240-1. [DOI] [PubMed] [Google Scholar]
- Stone V. E., Mauch M. Y., Steger K., Janas S. F., Craven D. E. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med. 1997 Mar;12(3):150–157. doi: 10.1007/s11606-006-5022-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wenger N. K., Speroff L., Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993 Jul 22;329(4):247–256. doi: 10.1056/NEJM199307223290406. [DOI] [PubMed] [Google Scholar]